Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 2
2003 2
2004 3
2005 2
2006 1
2010 1
2011 2
2012 3
2014 1
2015 2
2016 3
2017 1
2018 2
2019 3
2020 3
2021 4
2022 2
2023 1
2024 7
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Consequences of Sarcoidosis.
Drent M, Strookappe B, Hoitsma E, De Vries J. Drent M, et al. Among authors: hoitsma e. Clin Chest Med. 2015 Dec;36(4):727-37. doi: 10.1016/j.ccm.2015.08.013. Epub 2015 Sep 26. Clin Chest Med. 2015. PMID: 26593145 Review.
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial.
Coerver EME, Fung WH, de Beukelaar J, Bouvy WH, Canta LR, Gerlach OHH, Hoitsma E, Hoogervorst ELJ, de Jong BA, Kalkers NF, van Kempen ZLE, Lövenich H, van Munster CEP, van Oosten BW, Smolders J, Vennegoor A, Zeinstra EMPE, Barrantes-Cepas M, Kooij G, Schoonheim MM, Lissenberg-Witte BI, Teunissen CE, Moraal B, Barkhof F, Uitdehaag BMJ, Mostert J, Killestein J, Strijbis EMM. Coerver EME, et al. Among authors: hoitsma e. JAMA Neurol. 2025 Feb 1;82(2):123-131. doi: 10.1001/jamaneurol.2024.4164. JAMA Neurol. 2025. PMID: 39652340 Free PMC article. Clinical Trial.
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
Toorop AA, Wessels MH, Boonkamp L, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, van Munster CE, Vennegoor A, Mostert JP, Wokke BH, Kalkers NF, Hoogervorst EL, van Eijk JJ, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige L, Kloosterziel ME, Arnoldus EP, van Dijk GW, Bouvy WH, Strijbis EM, van Oosten BW, de Jong BA, Uitdehaag BM, Rispens T, Killestein J, van Kempen ZL, Teunissen CE. Toorop AA, et al. Among authors: hoitsma e. Mult Scler. 2024 Nov;30(13):1683-1688. doi: 10.1177/13524585241293940. Epub 2024 Nov 4. Mult Scler. 2024. PMID: 39494701 Free PMC article.
Neurosarcoidosis: a clinical dilemma.
Hoitsma E, Faber CG, Drent M, Sharma OP. Hoitsma E, et al. Lancet Neurol. 2004 Jul;3(7):397-407. doi: 10.1016/S1474-4422(04)00805-1. Lancet Neurol. 2004. PMID: 15207796 Review.
COVID-19 in multiple sclerosis: The Dutch experience.
Loonstra FC, Hoitsma E, van Kempen ZL, Killestein J, Mostert JP. Loonstra FC, et al. Among authors: hoitsma e. Mult Scler. 2020 Sep;26(10):1256-1260. doi: 10.1177/1352458520942198. Epub 2020 Jul 14. Mult Scler. 2020. PMID: 32662742 Free PMC article.
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS).
Fung WH, Wessels MHJ, Coerver EME, de Beukelaar J, Bouvy WH, Canta LR, Gerlach OHH, Hoitsma E, Hoogervorst ELJ, de Jong BA, Kalkers NF, van Kempen ZLE, Lövenich H, van Munster CEP, van Oosten BW, Smolders J, Vennegoor A, Zeinstra EMPE, Barrantes-Cepas M, Kooij G, Schoonheim MM, Lissenberg-Witte BI, Moraal B, Barkhof F, Uitdehaag BMJ, Mostert J, Teunissen CE, Killestein J, Strijbis EMM. Fung WH, et al. Among authors: hoitsma e. J Neurol. 2025 Jul 23;272(8):530. doi: 10.1007/s00415-025-13231-9. J Neurol. 2025. PMID: 40699373 Free PMC article. Clinical Trial.
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.
Gelissen LMY, Toorop AA, Schipper PM, Hoitsma E, Zeinstra EMPE, van Rooij LC, van Munster CEP, Vennegoor A, Mostert J, Wokke B, Kalkers NF, Hoogervorst ELJ, van Eijk J, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige LGF, Kloosterziel ME, Arnoldus EPJ, Bouvy WH, Strijbis EM, Oosten BV, De Jong BA, Uitdehaag BMJ, Lissenberg-Witte BI, Loeff FC, Rispens T, Killestein J, van Kempen ZLE. Gelissen LMY, et al. Among authors: hoitsma e. J Neurol Neurosurg Psychiatry. 2025 Mar 25:jnnp-2024-335761. doi: 10.1136/jnnp-2024-335761. Online ahead of print. J Neurol Neurosurg Psychiatry. 2025. PMID: 40132877 Free article.
45 results